Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (111-120 of 189) with videos related to

Pageof 19
Sort By:
Expert Opinion on Drug Safety|July 31, 2018
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting SystemIppazio Cosimo Antonazzo, Emanuel Raschi, Emanuele Forcesi, et al.
Acta Diabetologica|November 7, 2019
Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with cautionIppazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, et al.
Drug Safety|July 8, 2023
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research StudyMichele Fusaroli, Francesco Salvo, Claire Bernardeau, et al.
British Journal of Clinical Pharmacology|February 18, 2015
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemEmanuel Raschi, Elisabetta Poluzzi, Ariola Koci, et al.
European Journal of Clinical Pharmacology|September 4, 2012
Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and SwedenCarlo Piccinni, Emanuel Raschi, Elisabetta Poluzzi, et al.
European Journal of Clinical Pharmacology|January 8, 2008
Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in ItalyElisabetta Poluzzi, Petar Strahinja, Monica Lanzoni, et al.
Aging|October 7, 2020
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative databaseFloor Swart, Giampaolo Bianchi, Jacopo Lenzi, et al.
The Journal of Clinical Endocrinology and Metabolism|June 15, 2022
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Francesco Massari, et al.
Drug Safety|May 24, 2022
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting SystemAnna Gaimari, Michele Fusaroli, Emanuel Raschi, et al.
European Journal of Clinical Pharmacology|December 15, 2010
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage studyElisabetta Poluzzi, Carlo Piccinni, Paolo Carta, et al.
Pageof 19

Showing results (111-120 of 189) with videos related to

Sort By:
Pageof 19
Expert Opinion on Drug Safety|July 31, 2018
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting SystemIppazio Cosimo Antonazzo, Emanuel Raschi, Emanuele Forcesi, et al.
Acta Diabetologica|November 7, 2019
Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with cautionIppazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, et al.
Drug Safety|July 8, 2023
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research StudyMichele Fusaroli, Francesco Salvo, Claire Bernardeau, et al.
British Journal of Clinical Pharmacology|February 18, 2015
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemEmanuel Raschi, Elisabetta Poluzzi, Ariola Koci, et al.
European Journal of Clinical Pharmacology|September 4, 2012
Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and SwedenCarlo Piccinni, Emanuel Raschi, Elisabetta Poluzzi, et al.
European Journal of Clinical Pharmacology|January 8, 2008
Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in ItalyElisabetta Poluzzi, Petar Strahinja, Monica Lanzoni, et al.
Aging|October 7, 2020
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative databaseFloor Swart, Giampaolo Bianchi, Jacopo Lenzi, et al.
The Journal of Clinical Endocrinology and Metabolism|June 15, 2022
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Francesco Massari, et al.
Drug Safety|May 24, 2022
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting SystemAnna Gaimari, Michele Fusaroli, Emanuel Raschi, et al.
European Journal of Clinical Pharmacology|December 15, 2010
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage studyElisabetta Poluzzi, Carlo Piccinni, Paolo Carta, et al.
Pageof 19